Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Damoctocog alfa pegol→

Damoctocog alfa pegol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1363853-26-2
Molecular formula
Not available
Molecular weight
Not available
Drug class
Pegylated recombinant human coagulation factor VIIIextended-half-life factor VIII replacement biologic
Mechanism of action
Replaces deficient or dysfunctional coagulation factor VIII, acting as a cofactor for activated factor IX in the intrinsic tenase complex to activate factor X and support thrombin generation and fibrin clot formation.
Indications / reported uses
  • Treatment and prophylaxis of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency), including perioperative management, under the product-specific JIVI indication; inhibitor status and age criteria apply

Sources: US DailyMed — JIVI (damoctocog alfa pegol) · EMA EPAR — Jivi · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Damoctocog alfa pegol Environmental Risk Assessment (ERA) (the Damoctocog alfa pegol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.